Novel mechanism in microbiota-brain communication: the role of the hepatoportal region

微生物群-大脑通讯的新机制:肝门区的作用

基本信息

  • 批准号:
    10382242
  • 负责人:
  • 金额:
    $ 38.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-05 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Signals from peripheral tissues play an important role in aligning sleep-wake activity with the metabolic, nutri- tional and immune status of the organism. The intestinal microbiota is an essential source of such signals through the production of bacterial metabolites, e.g., short-chain fatty acids (SCFAs), and the release of bacterial cell wall components, lipopolysaccharide (LPS) and peptidoglycans. The long-term objective is to identify mechanisms of microbiota-brain communications and its relevance to sleep regulation. The objective of the present proposal is to investigate the newly discovered sleep-promoting viscerosensory mechanism in the hepatoportal region. Activation of hepatoportal sensors by SCFAs and bacterial cell wall products is a potent sleep-promoting signal. The central hypothesis is that bacterial products, such as LPS that translocate from the intestinal lumen to the liver via the portal vein, activate hepatic macrophages. Macrophages, in turn, secrete prostaglandins locally, which activate the sensory neurons of the hepatic vagus. Vagus carries somnogenic signal to the nucleus tractus solitarius, a component of brain stem sleep circuits. In three specific aims, we will 1) determine the role of hepatic macrophages in LPS-induced sleep in macrophage-depleted rats, 2) determine the contribution of hepatic prostaglandin E2 in sleep signaling 3) determine the contribution of hepatic vagal afferents in hepatoportal sleep induction. The concept of microbiota-gut-brain axis is viewed as a major paradigm shift in neuroscience. Changes in the composition of microbiota as well as increased translocation of microbial products to the systemic circulation are related to pathological conditions, including disorders of the central nervous system. Identifying the role of bacterial products in sleep regulation is important because the gut flora is susceptible to changes in diet, environment, food additives and antibiotic treatment, which could lead to altered sleep, but it can also provide an easily accessible target for translational research to improve sleep.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LEVENTE KAPAS其他文献

LEVENTE KAPAS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LEVENTE KAPAS', 18)}}的其他基金

Novel mechanism in microbiota-brain communication: the role of the hepatoportal region
微生物群-大脑通讯的新机制:肝门区的作用
  • 批准号:
    10600138
  • 财政年份:
    2020
  • 资助金额:
    $ 38.25万
  • 项目类别:
SLEEP REGULATION--INVOLVEMENT OF CHOLECYSTOKININ
睡眠调节——缩胆囊素的参与
  • 批准号:
    2268458
  • 财政年份:
    1994
  • 资助金额:
    $ 38.25万
  • 项目类别:
SLEEP REGULATION INVOLVEMENT OF CHOLECYSTOKININ
缩胆囊素参与的睡眠调节
  • 批准号:
    2379670
  • 财政年份:
    1994
  • 资助金额:
    $ 38.25万
  • 项目类别:
SLEEP REGULATION--INVOLVEMENT OF CHOLECYSTOKININ
睡眠调节——缩胆囊素的参与
  • 批准号:
    2268460
  • 财政年份:
    1994
  • 资助金额:
    $ 38.25万
  • 项目类别:
SLEEP REGULATION INVOLVEMENT OF CHOLECYSTOKININ
缩胆囊素参与的睡眠调节
  • 批准号:
    2703003
  • 财政年份:
    1994
  • 资助金额:
    $ 38.25万
  • 项目类别:
SLEEP REGULATION INVOLVEMENT OF CHOLECYSTOKININ
缩胆囊素参与的睡眠调节
  • 批准号:
    2416310
  • 财政年份:
    1994
  • 资助金额:
    $ 38.25万
  • 项目类别:
SLEEP REGULATION--INVOLVEMENT OF CHOLECYSTOKININ
睡眠调节——缩胆囊素的参与
  • 批准号:
    2268459
  • 财政年份:
    1994
  • 资助金额:
    $ 38.25万
  • 项目类别:
SLEEP REGULATION--INVOLVEMENT OF CHOLECYSTOKININ
睡眠调节——缩胆囊素的参与
  • 批准号:
    3510010
  • 财政年份:
    1993
  • 资助金额:
    $ 38.25万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了